Last reviewed · How we verify
Boehringer Ingelheim — Portfolio Competitive Intelligence Brief
53 marketed
0 filed
2 Phase 3
10 Phase 2
43 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dabigatran Etexilate | DABIGATRAN | marketed | Cardiovascular | 2025-01-01 | ||
| Jascayd | NERANDOMILAST | marketed | Immunology | 2025-01-01 | ||
| Hernexeos | ZONGERTINIB | marketed | Kinase Inhibitor [EPC] | Oncology | 2025-01-01 | |
| Spevigo | SPESOLIMAB | marketed | Interleukin-36 Receptor Antagonist [EPC] | Interleukin-1 receptor-like 2 | Immunology | 2022-01-01 |
| Praxbind | IDARUCIZUMAB | marketed | Humanized Monoclonal Antibody Fragment [EPC] | dabigatran and its acylglucuronide metabolites | Metabolic | 2015-01-01 |
| Ofev | NINTEDANIB | marketed | Kinase Inhibitor | Receptor-type tyrosine-protein kinase FLT3 | Oncology | 2014-01-01 |
| Striverdi Respimat | OLODATEROL | marketed | beta2-Adrenergic Agonist | Beta-2 adrenergic receptor | Respiratory | 2014-01-01 |
| Jardiance | empagliflozin | marketed | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | SGLT2 | Metabolic | 2014-01-01 |
| Gilotrif | afatinib | marketed | Kinase Inhibitor [EPC] | Epidermal growth factor receptor | Oncology | 2013-01-01 |
| Tradjenta | LINAGLIPTIN | marketed | Dipeptidyl Peptidase 4 Inhibitor [EPC] | Dipeptidyl peptidase 4 | Metabolic | 2011-01-01 |
| Tradjenta | BI 1356 | marketed | Dipeptidyl Peptidase 4 Inhibitor [EPC] | Dipeptidyl peptidase 4 | Metabolic | 2011-01-01 |
| Pradaxa | dabigatran-etexilate | marketed | Direct thrombin inhibitor | Thrombin (serine protease) | Cardiovascular | 2010-01-01 |
Therapeutic area mix
- Other · 13
- Metabolic · 8
- Oncology · 6
- Cardiovascular · 6
- Immunology · 6
- Respiratory · 2
- Neuroscience · 1
- Urology · 1
Recent regulatory actions (last 90 days)
- — Ofev · FDA · approved · US
- — Ofev · FDA · approved · US
- — Ofev · FDA · approved · US
- — Ofev · FDA · approved · US
- — Ofev · SFDA · likely_approved · SA
- — Ofev · MOH · likely_approved · AE
- — Ofev · MFDS · likely_approved · KR
- — Ofev · MOH · likely_approved · IL
- — Ofev · HSA · likely_approved · SG
- — Mexitil · FDA · approved · US
- — Hernexeos · FDA · approved · US
- — Jascayd · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Tradjenta · 8883805*PED · US
- — Tradjenta · 7713938 · US
- — Tradjenta · 11033552 · US
- — Tradjenta · 9173859 · US
- — Tradjenta · 8673927 · US
- — Pradaxa · 7866474 · US
- — Tradjenta · 7713938*PED · US
- — Tradjenta · 8673927*PED · US
- — Tradjenta · 11033552*PED · US
- — Tradjenta · 9173859*PED · US
- — Pradaxa · 7866474*PED · US
- — Tradjenta · 7579449 · US
- — Tradjenta · 7579449*PED · US
- — Viramune · 8460704 · Method of Use · US
- — Tradjenta · 9415016 · US
- — Tradjenta · 10022379 · US
- — Tradjenta · 10973827 · US
- — Tradjenta · 9486526 · US
- — Tradjenta · 10034877 · US
- — Tradjenta · 9415016*PED · US
- — Tradjenta · 10022379*PED · US
- — Tradjenta · 10973827*PED · US
- — Tradjenta · 8551957 · US
- — Tradjenta · 9486526*PED · US
- — Tradjenta · 10034877*PED · US
- — Tradjenta · 8551957*PED · US
- — Tradjenta · 9155705 · US
- — Mobic · 10709713 · Method of Use · US
- — Mobic · 9974746 · Formulation · US
- — Mobic · 11253478 · Formulation · US
Competitive overlap (companies sharing drug classes)
- · 7 shared drug classes
- Novartis · 4 shared drug classes
- Pfizer · 4 shared drug classes
- Merck & Co. · 3 shared drug classes
- Bayer · 3 shared drug classes
- Sanofi · 3 shared drug classes
- Ain Shams University · 2 shared drug classes
- Eli Lilly · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Boehringer Ingelheim:
- Boehringer Ingelheim pipeline updates — RSS
- Boehringer Ingelheim pipeline updates — Atom
- Boehringer Ingelheim pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Boehringer Ingelheim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/boehringer-ingelheim. Accessed 2026-05-16.